Sumitomo Pharma America, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1984-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.sunovion.com
A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2018-06-27
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT02275481
- Locations
- 🇺🇸
S. Carolina Pharmaceutical Research, Spartanburg, South Carolina, United States
🇺🇸Swedish Medical Center, Seattle, Washington, United States
🇺🇸PMG Research of Wilmington, Wilmington, North Carolina, United States
A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2014-09-05
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Registration Number
- NCT02232646
A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors
- First Posted Date
- 2014-09-05
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT02232620
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer
- First Posted Date
- 2014-09-05
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT02232633
- Locations
- 🇨🇦
The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
🇨🇦University of Calgary, Calgary, Alberta, Canada
🇨🇦Princess Margaret Hospital, Toronto, Ontario, Canada
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 139
- Registration Number
- NCT02231723
- Locations
- 🇺🇸
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Virginia Oncology Associates, Norfolk, Virginia, United States
A Study to Examine APL-130277 in Patients With Parkinson's Disease
- First Posted Date
- 2014-08-29
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02228590
- Locations
- 🇺🇸
Banner Sun Health Research Institute, Sun City, Arizona, United States
🇺🇸Rocky Mountain Movement Disorders Center, Englewood, Colorado, United States
🇺🇸Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States
Dasotraline SEP360-105 Pediatric PK/PD Study
- Conditions
- Interventions
- First Posted Date
- 2014-07-21
- Last Posted Date
- 2015-03-31
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT02195167
- Locations
- 🇺🇸
MCB Clinical Research Centers, LLC, Colorado Springs, Colorado, United States
🇺🇸Palm Springs Research Institute, Hialeah, Florida, United States
🇺🇸iResearch Atlanta, LLC, Decatur, Georgia, United States
A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-07-01
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 714
- Registration Number
- NCT02178956
- Locations
- 🇺🇸
Metro-Minnesota NCI CORP, Saint Louis Park, Minnesota, United States
🇧🇬Multiprofile hospital for active treatment, Sofia, Bulgaria
🇷🇴Institutul Regional de Oncologie Iasi, Lasi, Romania
Open-label Safety Study in Adults With ADHD
- Conditions
- Interventions
- First Posted Date
- 2014-06-10
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 724
- Registration Number
- NCT02160262
- Locations
- 🇺🇸
Premeir Psychiatric Research Institute, LLC, Lincoln, Nebraska, United States
🇺🇸Pillar Clinical Research, LLC, Dallas, Texas, United States
🇺🇸Family Psychiatry of the Woodlands, The Woodlands, Texas, United States
A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-05-30
- Last Posted Date
- 2016-04-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT02150499
- Locations
- 🇺🇸
Willis-Knighton Physician Network / Portico Pediatrics, Shreveport, Louisiana, United States
🇺🇸Capital Pediatrics & Adolescent Center PLLC, Raleigh, North Carolina, United States
🇺🇸Capitol Pediatric & Adolescent Center PLLC, Raleigh, North Carolina, United States